[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579131":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":33,"locations":37,"responsibleParty":51,"collaborators":33,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":33,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":33,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":33,"overallStatus":73,"whyStopped":33,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Vertex Pharmaceuticals Incorporated","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Part A: SUZ with Drospirenone\u002FEthinyl Estradiol (DRSP\u002FEE)","EXPERIMENTAL","Participants will receive a single dose of DRSP\u002FEE on Days 1 and 20. Participants will also receive SUZ every 12 hours (q12h) from Days 7 through 25.",[13,14],"Drug: Suzetrigine","Drug: DRSP\u002FEE",{"label":16,"type":10,"description":17,"interventionNames":18},"Part B: SUZ with Norgestimate\u002FEthinyl Estradiol (NGM\u002FEE)","Participants will receive a single dose NGM\u002FEE on Days 1 and 22. Participants will also receive SUZ every 12 hours (q12h) from Days 9 through 29.",[13,19],"Drug: NGM\u002FEE",[21,29,34],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Suzetrigine","Tablets for Oral Administration.",[9,16],[27,28],"VX-548","SUZ",{"type":22,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRSP\u002FEE","Combination Tablets for Oral Administration.",[9],null,{"type":22,"name":35,"description":31,"armGroupLabels":36,"otherNames":33},"NGM\u002FEE",[16],[38],{"facility":39,"status":33,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":33},"Celerion - Tempe","Tempe","Arizona","85283","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-111.90931,33.41477,{"lat":49,"lon":48},{"type":52,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100579131","phase-1-evaluation-of-the-effect-of-suzetrigine-suz-on-the-pharmacokinetics-of-oral-contraceptives-in-healthy-female-participants-100579131",false,"NCT06820307","Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants","A Phase 1, Open-label Study to Evaluate the Effect of Suzetrigine on the Pharmacokinetics of Oral Contraceptives in Healthy Female Subjects","Key Inclusion Criteria:\n\n* Body mass index of 18.0 to 30.0 kilogram per meter square (Kg\u002Fm\\^2)\n* A total body weight greater than (\\>) 50 kilogram (kg)\n* Nonsmoker or ex-smoker for at least 12 months before screening\n\nKey Exclusion Criteria:\n\n* History of febrile or acute illness that has not fully resolved by 14 days before the first dose of study drug\n* Any condition possibly affecting drug absorption, distribution, metabolism, or excretion\n* Relative contraindications to hormonal estrogen therapy that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant. This may include, but is not limited to, intolerance to hormonal contraceptives; hypertension; history of deep vein thrombosis; coronary artery disease; cardiovascular disease; systemic lupus erythematosus; migraine; history of breast or cervical cancer; cirrhosis; and history of liver cancer.\n\nOther protocol defined Inclusion\u002FExclusion criteria will apply.",true,"FEMALE","18 Years","50 Years",{"count":65,"type":66},50,"ACTUAL","INTERVENTIONAL",[69],"PHASE1","The purpose of this study is to evaluate the effect of SUZ on the pharmacokinetics of oral contraceptives.",[72],"Pain","COMPLETED","2025-05-28",{"date":76,"type":66},"2025-05-29",{"date":78,"type":66},"2025-02-25",{"date":80,"type":66},"2025-04-29",{"name":5,"class":6},1]